September 15th 2025
The decision from the Ministry of Health, Labour and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.
September 13th 2025
September 12th 2025
September 11th 2025
Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
April 18th 2025Panelists discuss how the growing role of combination therapies in EGFR-mutated non–small cell lung cancer (NSCLC) influences the choice between the MARIPOSA and FLAURA2 trials, considering overall survival data, multidisciplinary implementation, patient education, and their impact on first-line prescribing decisions.
Impressions of MARIPOSA Overall Survival and Potential Impact in Current SOC
April 11th 2025Panelists discuss how the significant overall survival (OS) benefit demonstrated by the new combination therapy (amivantamab-lazertinib) compared with standard monotherapy makes it a preferred treatment option for most patients despite a slightly increased toxicity and time commitment.
Brief Overview of Current Treatment Landscape for 1L EGFRm NSCLC
April 11th 2025Panelists discuss how the treatment landscape for EGFR-mutated lung cancer has evolved, with 3 strong options now available, including single-agent osimertinib and 2 combinations: osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA), with the latter showing significant overall survival benefits.
Evaluating ALK Inhibitors in Treatment Sequencing and Testing
Dr. Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib.